Cambridge Healthtech Institute’s 4th Annual

Targeting NASH

Drug Development for the Fatty and Fibrotic Liver

September 16-17, 2020


Non-alcoholic steatohepatitis (NASH) is a disease of the liver that starts with a build-up of fat in the organ and if inflammation is also present, results in fibrosis and dysfunction of the liver which can sometimes lead to cirrhosis, a type of liver cancer. No medical treatments for NASH yet exist, but drug discovery efforts against the disease are growing. There are a few drug candidates progressing in clinical trials, but there have also been a few recent failures. CHI’s Targeting NASH conference convenes leading drug discovery and development researchers and industry experts to share the latest publicly available results and discuss important questions in the field, such as which target classes still have potential, what are promising drug combinations, and best practices for clinical trial design.

Preliminary Agenda


Thyroid Hormone Receptor beta Agonist in Phase3 Clinical Trials for the Treatment of NASH: Resmetirom

Rebecca Taub, MD, CMO & President, R&D, Madrigal Pharmaceuticals

Optimized FXR Agonist with Best-in-Class Potential for NASH Treatment

Hubert Chen, MD, CMO, Metacrine Inc.

A Novel Fatty Acid Bile Acid Conjugate, Aramchol, in Clinical Development for NASH

Liat Hayardeny, PhD, Chief Scientific Officer, Galmed Pharmaceuticals

Targeting Galectin-3 in NASH

Alison Mackinnon, PhD, Director of Research, Galecto, Inc.

Aldafermin: Latest Clinical Results from an FGF-19 Agonist for the Treatment of NASH

Hsiao Lieu, MD, FACC, CMO and SVP, NGM Biopharmaceuticals, Inc.


Polypharmacy and NASH: Etiologies of the Disease and Methods of Treatment

Jason Wang, MD, Director, Business Development, Fortress Biotech


Please click here to continue to the agenda for Targeting Fibrosis

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252



For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286